Literature DB >> 25806177

Establishment of a malignant pleural effusion mouse model: pathogenesis pathways.

Kalliopi Domvri1, Paul Zarogoulidis2, Fotis Theodoropoulos3, Haidong Huang4, Konstantinos Zarogoulidis1.   

Abstract

Entities:  

Year:  2012        PMID： 25806177      PMCID： PMC4367555          DOI： 10.3978/j.issn.2218-6751.2012.08.02

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  25 in total

1.  Synergistic effect of interleukin-15 and interleukin-12 on antitumor activity in a murine malignant pleurisy model.

Authors:  K Kimura; H Nishimura; T Matsuzaki; T Yokokura; Y Nimura; Y Yoshikai
Journal:  Cancer Immunol Immunother       Date:  2000-05       Impact factor: 6.968

2.  Host-derived interleukin-5 promotes adenocarcinoma-induced malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Taylor P Sherrill; Sophia P Karabela; Kasia Goleniewska; Ioannis Kalomenidis; Charis Roussos; Barbara Fingleton; Fiona E Yull; R Stokes Peebles; Timothy S Blackwell
Journal:  Am J Respir Crit Care Med       Date:  2010-07-01       Impact factor: 21.405

3.  An improved orthotopic xenotransplant procedure for human lung cancer in SCID bg mice.

Authors:  A S Boehle; P Dohrmann; I Leuschner; H Kalthoff; D Henne-Bruns
Journal:  Ann Thorac Surg       Date:  2000-04       Impact factor: 4.330

4.  Nuclear factor-kappaB affects tumor progression in a mouse model of malignant pleural effusion.

Authors:  Georgios T Stathopoulos; Zhiwen Zhu; M Brett Everhart; Ioannis Kalomenidis; William E Lawson; Semra Bilaceroglu; Todd E Peterson; Daphne Mitchell; Fiona E Yull; Richard W Light; Timothy S Blackwell
Journal:  Am J Respir Cell Mol Biol       Date:  2005-10-06       Impact factor: 6.914

5.  Vascular endothelial growth factor levels and induction of permeability in malignant pleural effusions.

Authors:  B K Zebrowski; S Yano; W Liu; R M Shaheen; D J Hicklin; J B Putnam; L M Ellis
Journal:  Clin Cancer Res       Date:  1999-11       Impact factor: 12.531

6.  Crocidolite asbestos and SV40 are cocarcinogens in human mesothelial cells and in causing mesothelioma in hamsters.

Authors:  Barbara Kroczynska; Rochelle Cutrone; Maurizio Bocchetta; Haining Yang; Amira G Elmishad; Pamela Vacek; Maria Ramos-Nino; Brooke T Mossman; Harvey I Pass; Michele Carbone
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

7.  A novel SV40 TAg transgenic model of asbestos-induced mesothelioma: malignant transformation is dose dependent.

Authors:  Cleo Robinson; Ivonne van Bruggen; Amanda Segal; Melissa Dunham; Amanda Sherwood; Frank Koentgen; Bruce W S Robinson; Richard A Lake
Journal:  Cancer Res       Date:  2006-11-15       Impact factor: 12.701

8.  Relationships among tumor burden, tumor size, and the changing concentrations of fibrin degradation products and fibrinolytic factors in the pleural effusions of rabbits with VX2 lung tumors.

Authors:  Mark W C Hatton; Suzanne M R Southward; Bonnie L Ross; Bryan J Clarke; Gurmit Singh; Mary Richardson
Journal:  J Lab Clin Med       Date:  2006-01

9.  Metastatic human pleural ovarian cancer model constructed by orthotopic implantation of fresh histologically-intact patient carcinoma in nude mice.

Authors:  P Astoul; H G Colt; X Wang; R M Hoffman
Journal:  Anticancer Res       Date:  1993 Nov-Dec       Impact factor: 2.480

10.  Vinorelbine is effective for the malignant pleural effusion associated with lung cancer in mice.

Authors:  Ri Cui; Masakata Yoshioka; Fumiyuki Takahashi; Hiroyuki Ishida; Shinichiro Iwakami; Kazuhisa Takahashi
Journal:  Anticancer Res       Date:  2008 May-Jun       Impact factor: 2.480
View more
  1 in total

1.  DDMC-p53 gene therapy with or without cisplatin and microwave ablation.

Authors:  Wolfgang Hohenforst-Schmidt; Paul Zarogoulidis; Joshua Stopek; Thomas Vogl; Frank Hübner; J Francis Turner; Robert Browning; Konstantinos Zarogoulidis; Antonis Drevelegas; Konstantinos Drevelegas; Kaid Darwiche; Lutz Freitag; Harald Rittger
Journal:  Onco Targets Ther       Date:  2015-05-20       Impact factor: 4.147
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.